David Gervais1, Darryl King2, Patrick Kanda2, Nicholas Foote2, Lucy Elliott2, Phillip Brown2, Natacha O Lee3, Konstantinos Thalassinos3, Claire Pizzey4, Robert Rambo4, Thomas C Minshull5, Mark J Dickman5, Stuart Smith2. 1. Porton Biopharma Limited, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK. dave.gervais@portonbiopharma.com. 2. Porton Biopharma Limited, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK. 3. Institute of Structural and Molecular Biology, Division of Biosciences, Darwin Building Room 101A, University College London, Gower Street, London, WC1E 6BT, UK. 4. Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot, Oxfordshire, OX11 0DE, UK. 5. ChELSI Institute, Dept of Chemical and Biological Engineering, University of Sheffield, Mappin Street, Sheffield, S1 3JD, UK.
Abstract
PURPOSE: Erwinia chrysanthemi L-asparaginase (ErA) is an enzyme commonly used in the treatment regimen for Acute Lymphoblastic Leukaemia (ALL). Biopharmaceutical products such as ErA must be monitored for modifications such as deamidation, typically using ion-exchange chromatography (IEX). Analysis of clinical-grade ErA using native IEX resolves a number of enzymatically-active, acidic variants that were poorly characterised. METHODS: ErA IEX variants were isolated and fully characterised using capillary electrophoresis (cIEF), LC-MS and LC-MS/MS of proteolytic digests, and structural techniques including circular dichroism, small-angle X-ray scattering (SAXS) and ion-mobility mass spectrometry (IM-MS). RESULTS: LC-MS, MS/MS and cIEF demonstrated that all ErA isolates consist mainly of enzyme lacking primary-sequence modifications (such as deamidation). Both SAXS and IM-MS revealed a different conformational state in the most prominent acidic IEX peak. However, SAXS data also suggested conformational differences between the main peak and major acidic variant were minor, based on comparisons with crystal structures. CONCLUSIONS: IEX data for biopharmaceuticals such as ErA should be thoroughly characterised, as the most common modifications, such as deamidation, may be absent.
PURPOSE: Erwinia chrysanthemi L-asparaginase (ErA) is an enzyme commonly used in the treatment regimen for Acute Lymphoblastic Leukaemia (ALL). Biopharmaceutical products such as ErA must be monitored for modifications such as deamidation, typically using ion-exchange chromatography (IEX). Analysis of clinical-grade ErA using native IEX resolves a number of enzymatically-active, acidic variants that were poorly characterised. METHODS: ErA IEX variants were isolated and fully characterised using capillary electrophoresis (cIEF), LC-MS and LC-MS/MS of proteolytic digests, and structural techniques including circular dichroism, small-angle X-ray scattering (SAXS) and ion-mobility mass spectrometry (IM-MS). RESULTS: LC-MS, MS/MS and cIEF demonstrated that all ErA isolates consist mainly of enzyme lacking primary-sequence modifications (such as deamidation). Both SAXS and IM-MS revealed a different conformational state in the most prominent acidic IEX peak. However, SAXS data also suggested conformational differences between the main peak and major acidic variant were minor, based on comparisons with crystal structures. CONCLUSIONS: IEX data for biopharmaceuticals such as ErA should be thoroughly characterised, as the most common modifications, such as deamidation, may be absent.
Entities:
Keywords:
L-asparaginase; SAXS; deamidation; ion mobility; pH-induced conformational change
Authors: Gillian R Hilton; Konstantinos Thalassinos; Megan Grabenauer; Narinder Sanghera; Susan E Slade; Thomas Wyttenbach; Philip J Robinson; Teresa J T Pinheiro; Michael T Bowers; James H Scrivens Journal: J Am Soc Mass Spectrom Date: 2010-01-28 Impact factor: 3.109
Authors: Min Zhou; Nina Morgner; Nelson P Barrera; Argyris Politis; Shoshanna C Isaacson; Dijana Matak-Vinković; Takeshi Murata; Ricardo A Bernal; Daniela Stock; Carol V Robinson Journal: Science Date: 2011-10-21 Impact factor: 47.728
Authors: Erik G Marklund; Matteo T Degiacomi; Carol V Robinson; Andrew J Baldwin; Justin L P Benesch Journal: Structure Date: 2015-03-19 Impact factor: 5.006